// App-Quantinova.ai

5001 : A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12.

Researchers

Presenter

  • Goran Ahlgren

Principal Investigators

  • Per Flodgren

  • Teuvo L. J. Tammela

  • Pirkko Kellokumpu-Lehtinen

  • Michael Borre

  • Anders Angelsen

  • Jon Reidar Iversen

  • Asgerdur Sverrisdottir

  • Eirikur Jonsson

  • Lisa Sengelov

Medical Centers

  • Department of Hematology, Skane University Hospital, Lund University, Lund, Sweden

  • Lund University Hospital, Lund, Sweden

  • Tampere University Hospital, Department of Urology, Tampere, Finland

  • Department of Oncology, Tampere University Hospital, Tampere, Finland

  • Department of Urology, Aarhus University Hospital, Skejby Sygehus, Aarhus, Denmark

  • Norwegian University of Science and Technology, Trondheim, Norway

  • Department of Oncology, Oslo, Norway

  • Department of Oncology, Reykjavik, Iceland

  • Landspitali Unversity Hospital, Reykjavik, Iceland

  • Department of Oncology, KAS Herlev, Herlev, Denmark

Locations

  • Finland

  • Norway

  • Iceland

  • Denmark

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

Phase

  • III

Study Id's

  • NCT00376792

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved